|
First-line treatment with immune checkpoint inhibitors (ICI) for metastatic gastric and esophagogastric junction (EGJ) adenocarcinoma in Latin America: Sociedad Latinoamericana de Gastroenterología Oncológica (SLAGO) evidence-based recommendations. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; BMS; Lilly; Merck Serono; Raffo; SERVIER |
|
|
Consulting or Advisory Role - AstraZeneca; MSD; Roche |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Roche |
|
Paola Catherine Montenegro |
Employment - Merck Serono (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |